Skip to content

the effect of anaesthetic technique in patients undergoing NSCLC surgery- a multicenter study

he effect of anaesthetic technique on oxidative stress, pain and prognosis in patients undergoing NSCLC surgery- a multicenter study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040604
Enrollment
Unknown
Registered
2020-12-03
Start date
2020-12-07
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell lung cancer

Interventions

A:the sedative of induction and anesthesia maintenance is sevofluane
B:the sedative of induction and anesthesia maintenance is propofol
D:Paravertebral block pre-operation

Sponsors

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients who volunteered to participate in the study and signed written informed consent; 2) Patients aged 18 to 60 years at the time of signing the informed consent; 3) Planned radical resection of lung cancer under general anesthesia; 4) the American society of anesthesiologists I or II.

Exclusion criteria

Exclusion criteria: 1) Patients with a history of malignant tumor; 2) Patients who received preoperative chemotherapy or radiotherapy; 3) Patients with recent infection or taking immunosuppressive drugs; 4) BMI31; 5) Combined with hepatic and renal insufficiency, respiratory insufficiency, and cardiac insufficiency; 6) Contraindications for the use of drugs in the study; 7) Contraindications for paravertebral block, including severe coagulation dysfunction, puncture site infection, trauma or spinal surgery history; 8) Long-term drinking, long-term use of sedative drugs or antidepressants and other psychotropic drugs; 9) Patients who have participated in other pharmaceutical studies in the past month.

Design outcomes

Primary

MeasureTime frame
NRF2;NLRP3;ROS;GSH;IL-11;

Countries

China

Contacts

Public ContactLily Sun

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

lilysun0008@aliyun.com+86 0755-66618186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026